313 related articles for article (PubMed ID: 22971289)
1. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.
Switzer CH; Cheng RY; Ridnour LA; Glynn SA; Ambs S; Wink DA
Breast Cancer Res; 2012 Sep; 14(5):R125. PubMed ID: 22971289
[TBL] [Abstract][Full Text] [Related]
2. S-nitrosylation of Ras in breast cancer.
Marshall HE; Foster MW
Breast Cancer Res; 2012 Nov; 14(6):113. PubMed ID: 23167903
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
[TBL] [Abstract][Full Text] [Related]
4. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.
Glynn SA; Boersma BJ; Dorsey TH; Yi M; Yfantis HG; Ridnour LA; Martin DN; Switzer CH; Hudson RS; Wink DA; Lee DH; Stephens RM; Ambs S
J Clin Invest; 2010 Nov; 120(11):3843-54. PubMed ID: 20978357
[TBL] [Abstract][Full Text] [Related]
5. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer.
Ambs S; Glynn SA
Cell Cycle; 2011 Feb; 10(4):619-24. PubMed ID: 21293193
[TBL] [Abstract][Full Text] [Related]
6. S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer.
Switzer CH; Glynn SA; Cheng RY; Ridnour LA; Green JE; Ambs S; Wink DA
Mol Cancer Res; 2012 Sep; 10(9):1203-15. PubMed ID: 22878588
[TBL] [Abstract][Full Text] [Related]
7. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
Heinecke JL; Ridnour LA; Cheng RY; Switzer CH; Lizardo MM; Khanna C; Glynn SA; Hussain SP; Young HA; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6323-8. PubMed ID: 24733928
[TBL] [Abstract][Full Text] [Related]
8. p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells.
Phelps M; Darley M; Primrose JN; Blaydes JP
Cancer Res; 2003 May; 63(10):2616-23. PubMed ID: 12750288
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer.
Switzer CH; Glynn SA; Ridnour LA; Cheng RY; Vitek MP; Ambs S; Wink DA
Trends Pharmacol Sci; 2011 Nov; 32(11):644-51. PubMed ID: 21893353
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells.
López-Sánchez LM; Mena R; Guil-Luna S; Mantrana A; Peñarando J; Toledano-Fonseca M; Conde F; De la Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Lab Invest; 2021 Mar; 101(3):292-303. PubMed ID: 33262438
[TBL] [Abstract][Full Text] [Related]
11. Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.
Basudhar D; Somasundaram V; de Oliveira GA; Kesarwala A; Heinecke JL; Cheng RY; Glynn SA; Ambs S; Wink DA; Ridnour LA
Antioxid Redox Signal; 2017 Jun; 26(18):1044-1058. PubMed ID: 27464521
[TBL] [Abstract][Full Text] [Related]
12. LINE-1 ORF-1p functions as a novel HGF/ETS-1 signaling pathway co-activator and promotes the growth of MDA-MB-231 cell.
Yang Q; Feng F; Zhang F; Wang C; Lu Y; Gao X; Zhu Y; Yang Y
Cell Signal; 2013 Dec; 25(12):2652-60. PubMed ID: 24012497
[TBL] [Abstract][Full Text] [Related]
13. Assessing the predictive response of a simple and sensitive blood-based biomarker between estrogen-negative solid tumors.
Mohan S; Patel S; Barlow D; Rojas AC
Adv Med Sci; 2020 Sep; 65(2):424-428. PubMed ID: 32919119
[TBL] [Abstract][Full Text] [Related]
14. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
15. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion.
Qi X; Tang J; Loesch M; Pohl N; Alkan S; Chen G
Cancer Res; 2006 Aug; 66(15):7540-7. PubMed ID: 16885352
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element.
Newberry EP; Willis D; Latifi T; Boudreaux JM; Towler DA
Mol Endocrinol; 1997 Jul; 11(8):1129-44. PubMed ID: 9212060
[TBL] [Abstract][Full Text] [Related]
17. Assessing N
Mohan S; Greenstein I; Ng C; Frazier K; Nguyen G; Harding L; Barlow D
Amino Acids; 2018 Apr; 50(3-4):373-382. PubMed ID: 29260322
[TBL] [Abstract][Full Text] [Related]
18. Elk-3 is a transcriptional repressor of nitric-oxide synthase 2.
Chen YH; Layne MD; Chung SW; Ejima K; Baron RM; Yet SF; Perrella MA
J Biol Chem; 2003 Oct; 278(41):39572-7. PubMed ID: 12896968
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of mixed lineage kinase 3 by estrogen and its implication in ER-positive breast cancer pathogenesis.
Viswakarma N; Nair RS; Sondarva G; Das S; Ibrahimi L; Chen Z; Sinha S; Rana B; Rana A
Oncotarget; 2017 May; 8(20):33172-33184. PubMed ID: 28388540
[TBL] [Abstract][Full Text] [Related]
20. S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer.
Switzer CH; Ridnour LA; Cheng R; Heinecke J; Burke A; Glynn S; Ambs S; Wink DA
For Immunopathol Dis Therap; 2012; 3(2):117-124. PubMed ID: 23543871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
